This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.
What you’ll discover:
- Key trends shaping the pharmaceutical formulation sector
- Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
- Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
- And more!
Don’t miss your chance to access this exclusive report ! Access now – it’s free
I think it actually an interesting idea, if public bodies invest in biosimiliarty studies. They could offer low priced medicine to third world countries and cross-finance them by selling the same medicine to first world countries for a higher price. It however would be important that the rational which biosimilars are chosen fur such projects should be as transparent as possible. It would be bad if politicians could take influence on these decisions to harm foreign pharmaceutical companies. Additionally, it would be interesting what happens with the profits gained by this biosimiliar. In the end the WHO could establish itself as a highly subsidized low price pharmaceutical company, which could be a big problem for a large number of privately owned (not subsidized) companies.